@article{03d0bba5d24f4277943c6a0ff513fb58,
title = "Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques",
abstract = "Developing an intervention that results in virologic control following discontinuation of antiretroviral therapy (ART) is a major objective of HIV-1 cure research. In this study, we investigated the therapeutic efficacy of a vaccine consisting of adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) with or without an SIV Envelope (Env) gp140 protein with alum adjuvant in combination with the TLR7 agonist vesatolimod (GS-9620) in 36 ART-suppressed, SIVmac251-infected rhesus macaques. Ad26/MVA therapeutic vaccination led to robust humoral and cellular immune responses, and the Env protein boost increased antibody responses. Following discontinuation of ART, virologic control was observed in 5/12 animals in each vaccine group, compared with 0/12 animals in the sham control group. These data demonstrate therapeutic efficacy of Ad26/MVA vaccination with vesatolimod but no clear additional benefit of adding an Env protein boost. SIV-specific cellular immune responses correlated with virologic control. Our findings show partial efficacy of therapeutic vaccination following ART discontinuation in SIV-infected rhesus macaques.",
author = "Ventura, {John D.} and Nkolola, {Joseph P.} and Abishek Chandrashekar and Borducchi, {Erica N.} and Jinyan Liu and Mercado, {Noe B.} and Hope, {David L.} and Giffin, {Victoria M.} and Katherine McMahan and Romas Geleziunas and Murry, {Jeffrey P.} and Yunling Yang and Lewis, {Mark G.} and Pau, {Maria G.} and Frank Wegmann and Hanneke Schuitemaker and Fray, {Emily J.} and Kumar, {Mithra R.} and Siliciano, {Janet D.} and Siliciano, {Robert F.} and Robb, {Merlin L.} and Michael, {Nelson L.} and Barouch, {Dan H.}",
note = "Funding Information: We thank the administrative and research staff at Beth Israel Deaconess Medical Center and our collaborators at Gilead Sciences, Janssen Vaccines and Prevention, and the Ragon Institute of MIT, MGH and Harvard. We acknowledge support from the National Institutes of Health (AI124377, AI126603, AI128751, AI164556), the Henry Jackson Foundation (2018-CHEDA-001-796529), and Janssen Infectious Diseases and Vaccines. The views expressed in this manuscript are those of the authors and do not represent the official views of Harvard Medical School, Beth Israel Deaconess Medical Center, Janssen, Gilead Sciences, the Department of the Army, or the Department of Defense. Funding Information: We thank the administrative and research staff at Beth Israel Deaconess Medical Center and our collaborators at Gilead Sciences, Janssen Vaccines and Prevention, and the Ragon Institute of MIT, MGH and Harvard. We acknowledge support from the National Institutes of Health (AI124377, AI126603, AI128751, AI164556), the Henry Jackson Foundation (2018-CHEDA-001-796529), and Janssen Infectious Diseases and Vaccines. The views expressed in this manuscript are those of the authors and do not represent the official views of Harvard Medical School, Beth Israel Deaconess Medical Center, Janssen, Gilead Sciences, the Department of the Army, or the Department of Defense. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
doi = "10.1038/s41541-022-00477-x",
language = "English (US)",
volume = "7",
journal = "npj Vaccines",
issn = "2059-0105",
publisher = "Nature Publishing Group",
number = "1",
}